Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107


Epigenetics of human papillomaviruses.

Johannsen E, Lambert PF.

Virology. 2013 Oct;445(1-2):205-12. doi: 10.1016/j.virol.2013.07.016. Epub 2013 Aug 13.


TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16.

Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V, Mansour M, Vincent I, Gissmann L, Iftner T, Sideri M, Stubenrauch F, Tommasino M.

J Immunol. 2007 Mar 1;178(5):3186-97.


Biology and pathological associations of the human papillomaviruses: a review.

Cheah PL, Looi LM.

Malays J Pathol. 1998 Jun;20(1):1-10. Review.


Characterization of the methylation patterns in human papillomavirus type 16 viral DNA in head and neck cancers.

Park IS, Chang X, Loyo M, Wu G, Chuang A, Kim MS, Chae YK, Lyford-Pike S, Westra WH, Saunders JR, Sidransky D, Pai SI.

Cancer Prev Res (Phila). 2011 Feb;4(2):207-17. doi: 10.1158/1940-6207.CAPR-10-0147.


Pathogenesis of human papillomaviruses in differentiating epithelia.

Longworth MS, Laimins LA.

Microbiol Mol Biol Rev. 2004 Jun;68(2):362-72. Review.


DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri.

Melsheimer P, Vinokurova S, Wentzensen N, Bastert G, von Knebel Doeberitz M.

Clin Cancer Res. 2004 May 1;10(9):3059-63.


Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle.

Genther SM, Sterling S, Duensing S, Münger K, Sattler C, Lambert PF.

J Virol. 2003 Mar;77(5):2832-42.


Human papillomavirus infections: warts or cancer?

Chow LT, Broker TR.

Cold Spring Harb Perspect Biol. 2013 Jul 1;5(7). pii: a012997. doi: 10.1101/cshperspect.a012997. Review.


Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis.

Ganguly N, Parihar SP.

J Biosci. 2009 Mar;34(1):113-23. Review.


Nucleolin as activator of human papillomavirus type 18 oncogene transcription in cervical cancer.

Grinstein E, Wernet P, Snijders PJ, Rösl F, Weinert I, Jia W, Kraft R, Schewe C, Schwabe M, Hauptmann S, Dietel M, Meijer CJ, Royer HD.

J Exp Med. 2002 Oct 21;196(8):1067-78.


Suppression of HPV E6 and E7 expression by BAF53 depletion in cervical cancer cells.

Lee K, Lee AY, Kwon YK, Kwon H.

Biochem Biophys Res Commun. 2011 Aug 26;412(2):328-33. doi: 10.1016/j.bbrc.2011.07.098. Epub 2011 Jul 29.


The E2F5 repressor is an activator of E6/E7 transcription and of the S-phase entry in HPV18-associated cells.

Teissier S, Pang CL, Thierry F.

Oncogene. 2010 Sep 9;29(36):5061-70. doi: 10.1038/onc.2010.246. Epub 2010 Jul 19.


Genetic and epigenetic changes of HPV16 in cervical cancer differentially regulate E6/E7 expression and associate with disease progression.

Mazumder Indra D, Singh RK, Mitra S, Dutta S, Chakraborty C, Basu PS, Mondal RK, Roychoudhury S, Panda CK.

Gynecol Oncol. 2011 Dec;123(3):597-604. doi: 10.1016/j.ygyno.2011.08.004. Epub 2011 Sep 10.


Methylation of the human papillomavirus-18 L1 gene: a biomarker of neoplastic progression?

Turan T, Kalantari M, Calleja-Macias IE, Cubie HA, Cuschieri K, Villa LL, Skomedal H, Barrera-Saldaña HA, Bernard HU.

Virology. 2006 May 25;349(1):175-83. Epub 2006 Feb 10.


Silencing of multi-copy HPV16 by viral self-methylation and chromatin occlusion: a model for epigenetic virus-host interaction.

De-Castro Arce J, Göckel-Krzikalla E, Rösl F.

Hum Mol Genet. 2012 Apr 15;21(8):1693-705. doi: 10.1093/hmg/ddr604. Epub 2011 Dec 30.

Items per page

Supplemental Content

Write to the Help Desk